加替沙星和环丙沙星体外抗生素后效应期间大肠埃希菌形态学观察及膜电位和膜通透性变化

中国临床药理学与治疗学 ›› 2005, Vol. 10 ›› Issue (9): 1005-1009.

加替沙星和环丙沙星体外抗生素后效应期间大肠埃希菌形态学观察及膜电位和膜通透性变化

朱曼, 王睿, 张永青, 梁蓓蓓

解放军总医院药品保障中心, 北京 100853

收稿日期:2005-05-23 修回日期:2005-07-14 发布日期:2020-11-22
通讯作者: 王睿,女,教授,博士生导师,主要从事抗生素、药物基因组学研究。Tel:010-66937141 E-mail:zhucindy301@yahoo.com.cn
作者简介:朱曼,女,硕士,药师,主要从事临床药理研究。

Investigation of morphological characteristics, membrance potential and membance patency in Escherichia coli following ciprofloxacin exposure

ZHU Man, WANG Rui, ZHANG Yong-qing, LIANG Bei-bei

Department of Clinical Pharmacology, Chinese PLA General Hospital, Beijing 100853, China

Received:2005-05-23 Revised:2005-07-14 Published:2020-11-22

摘要/Abstract

摘要： 目的: 通过对加替沙星和环丙沙星体外抗生素后效应(PAE) 期间E.coliATCC25922 的形态学观察以及膜电位、膜通透性变化的研究, 以期为探讨PAE 形成机制提供实验依据。方法: 在不同时间点吸取加替沙星和环丙沙星抗PAE 期间的大肠埃希菌培养液, 用荧光探针碘化丙啶和DiBAC4(3) 进行染色, 应用荧光显微镜观察E.coliATCC25922 的形态学变化, 并采用流式细胞仪分析其膜电位、膜通透性变化。结果: 荧光显微镜结果表明:菌落计数法所测定的PAE 之后仍有丝状体存在, 但流式细胞仪结果表明加替沙星和环丙沙星PAE 期间E.coliATCC25922 膜电位及膜通透性与空白对照组比较无显著性差异。结论: 加替沙星和环丙沙星PAE 期间E.coli 菌体显著延长, 呈丝状体, 而其膜电位及膜通透性比较则无显著性变化, 提示丝状体形成与细胞膜变化不直接相关。

关键词: 加替沙星, 环丙沙星, 抗生素后效应, 大肠埃希菌

Abstract: AIM: To study the changes of bacterial ultrastructure, membrance potential and membrance patency of Escherichia coli during the postantibiotic effect after exposure to gatifloxacin and ciprofloxacin in order to investigate the mechanisms of PAE.METHODS: During the Postantibiotic effect after exposure to gatifloxacin and ciprofloxacin, the aliquots were taken from the bacterial culture at regular intervals.Then the fluorescence microscope was used to observe changes in bacterial ultrastructure and at the same time we studied the changes of membrance potential and membrance patency in Escherichia coli during the postantibiotic effect by flow cytometry in conjunction with fluorescent probes.RESULTS: The PAE phase characterized by filament formation after exposure to gatifloxacin by fluorescence microscopy, yet no significant changes in membrance potential and membrance patency of Escherichia coli were observed.CONCLUSION: Gatifloxacin and ciprofloxacin can induce filamentation, and this change is indifferent with membrance potential and membrance patency of Escherichia coli.

Key words: gatifloxacin, ciprofloxacin, Postantibiotic effect, Escherichia coli

中图分类号:

R978.1

朱曼, 王睿, 张永青, 梁蓓蓓. 加替沙星和环丙沙星体外抗生素后效应期间大肠埃希菌形态学观察及膜电位和膜通透性变化[J]. 中国临床药理学与治疗学, 2005, 10(9): 1005-1009.

ZHU Man, WANG Rui, ZHANG Yong-qing, LIANG Bei-bei. Investigation of morphological characteristics, membrance potential and membance patency in Escherichia coli following ciprofloxacin exposure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(9): 1005-1009.

参考文献

1 方翼, 王睿, 刘皈阳, 刘庆锋, 陈迁, 周亮, 等.3 种氟喹诺酮类药物抗生素后效应的研究[J].中国抗生素杂志,1997;22:67-70
2 Paster A, Peman J, Canton E.In vitro postanibiotic effect of sparfloxacin and ciprofloxacin against Pseudomonas aeruginosa and Enterococcus faecalis[J].J Antimicrob Chemother, 1994; 34:679
3 Jepras RI, Paul FE, Perason SC, WilkinsonMJ.Rapid assessment of antibiotic effects on escherichia coli by bis-(1, 3-Dibutylbarbituric acid) trimethine oxonol and flow cytometry [J].Antimicrobial Agents Chemother, 1997;41:2001-5
4 Novo DJ, Perlmutter NG, Hunt RH, Shaprio HM.Multiparameter flow cytometric analy sis of antibiotic effects on membrane potential, membrance permeability, and bacterial counts of staphy lococcus aureus and micrococcus luteus[J].Antimicrobial Agents Chemotherapy, 2000;44:827-34
5 Dougherty TJ, Saukkonen JJ.Membrane permeability changes associated with DNA gyrase inhibitors in Escherichia coli[J]. Antimicrobial Agents Chemotherapy, 1985;28:200-6
6 雷军, 王浴生, 黎世能.诺氟沙星对大肠杆菌2280 的扫描电镜观察[J].中国抗生素杂志, 1994;19:66-7
7 Elliott TSJ, Sheltion A, Greenwood D.The response of Escherichia coli to ciprofloxacin and norfloxacin[J].JMedMicrobiol, 1987;23:83-8
8 Diver JM, Wise R.Morphological and biochemical changes in Escherichia coli after exposure to ciprofloxacin[J].J Antimicrobial Chemotherapy, 1986;18:31-41
9 Piddock LJY, Walters RN.Bactercidal activities of five quinolones for escherichia coli strains with mutations in genes encoding the SOS response or cell division[J].Antimicrobial Agents Chemotherapy, 1992;36:819-25
10 Piddock LJY, Walters RN, Diver JM.Correlation of quinolone MIC and inhibition of DNA, RNA, and protein synthesis and induction of the SOS response in Escherichia coli[J].Antimicrobial Agents Chemotherapy, 1990;34:2331-6
11 Lewin CS, Howard BMA, Ratcliffe NT, et alSimth TT..4-Quinolones and the SOS response[J].J Med Microbiol, 1989; 29:139-144
12 Wicken HJ, Pinney RJ, Mason DJ, Gant VA.Flow cytomeric investigation of filamentation, membrane patency, and membrane potential in escherichia coli following ciprofloxacin exposure[J].Antimicrobial Agents Chemotherapy, 2000;44:682-7

[1]	邓莉, 田静. 白藜芦醇抑制大肠埃希菌O104∶H4诱导的结肠上皮细胞NLRP3炎症小体活化[J]. 中国临床药理学与治疗学, 2021, 26(2): 167-173.
[2]	李攀, 赵祎博, 李小丽, 李斌, 周红. 内毒素耐受状态小鼠对大肠埃希菌敏感性及促炎细胞因子水平变化的研究[J]. 中国临床药理学与治疗学, 2015, 20(3): 261-265.
[3]	李春杏, 付强, 朱珠. 利奈唑胺组织穿透性及在感染组织中的药效学[J]. 中国临床药理学与治疗学, 2015, 20(3): 349-355.
[4]	余梦辰, 潘夕春, 李小丽, 李军, 肖康康, 李斌, 周红. 青蒿琥酯增加小鼠腹腔巨噬细胞内化内毒素、大肠埃希菌的作用及可能机制[J]. 中国临床药理学与治疗学, 2012, 17(1): 40-46.
[5]	张菁, 郁继诚, 曹国英, 施耀国, 吴菊芳, 陈章景, 张婴元. 国产加替沙星片剂在中国男性健康受试者的临床药代动力学及生物等效性研究[J]. 中国临床药理学与治疗学, 2004, 9(5): 577-580.
[6]	张永青, 王睿, 朱曼, 张健鹏, 张咏梅, 同军. 原子力显微镜观察头孢美唑抗生素后效应期间大肠埃希菌形态学特征[J]. 中国临床药理学与治疗学, 2004, 9(10): 1123-1127.
[7]	梁蓓蓓, 刘庆锋, 赵铁梅, 朱曼, 方翼, 王睿. 甲磺酸加替沙星与其他4 种氟喹诺酮类药物对临床分离菌的体外抗菌活性比较[J]. 中国临床药理学与治疗学, 2004, 9(1): 48-51.
[8]	方翼, 王睿, 裴斐, 柴栋, 朱曼, 梁蓓蓓, 王锡萍. 连续口服甲磺酸加替沙星片的人体耐受性研究[J]. 中国临床药理学与治疗学, 2004, 9(1): 70-73.
[9]	柴栋, 王睿, 裴斐, 方翼, 朱曼, 王中孝. 克拉霉素与加替沙星联用对大鼠铜绿假单胞菌生物被膜肺部感染的治疗作用[J]. 中国临床药理学与治疗学, 2003, 8(6): 618-620.
[10]	王莹. 加替沙星片与左氧氟沙星片治疗轻中度急性下呼吸道感染的临床疗效比较[J]. 中国临床药理学与治疗学, 2003, 8(4): 434-437.
[11]	赵怀军, 王晖, 冯建青, 黄金水. 薄荷醇对环丙沙星粘膜吸收的影响¹[J]. 中国临床药理学与治疗学, 2002, 7(4): 314-316.
[12]	朱曼, 王睿. 第四代氟喹诺酮类抗菌药——加替沙星[J]. 中国临床药理学与治疗学, 2001, 6(4): 377-381.
[13]	贾志凡, 王维力, 翁福海. 环丙沙星对美吡达的药代学和药效学的影响[J]. 中国临床药理学与治疗学, 2000, 5(3): 238-240.
[14]	王睿, 方翼, 陈迁, 刘皈阳, 刘庆锋, 刘又宁. 20种抗菌药物对金黄色葡萄球菌抗生素后效应的研究[J]. 中国临床药理学与治疗学, 1999, 4(2): 146-149.
[15]	陈迁, 王睿, 方翼. 自动化微生物比浊法测定血清中环丙沙星浓度[J]. 中国临床药理学与治疗学, 1998, 3(3): 190-191.